Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole

Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D(2) receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify(®)). The drug was approved for this indication in the United States in 2002 and has received approval in the United States, Euro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kikuchi, Tetsuro, Maeda, Kenji, Suzuki, Mikio, Hirose, Tsuyoshi, Futamura, Takashi, McQuade, Robert D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340839/
https://www.ncbi.nlm.nih.gov/pubmed/33960741
http://dx.doi.org/10.1002/npr2.12180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340839/
https://www.ncbi.nlm.nih.gov/pubmed/33960741
http://dx.doi.org/10.1002/npr2.12180

Ejemplares similares